186 related articles for article (PubMed ID: 37159282)
1. Sirolimus-eluting airway stent reduces profibrotic Th17 cells and inhibits laryngotracheal stenosis.
Motz KM; Lina IA; Samad I; Murphy MK; Duvvuri M; Davis RJ; Gelbard A; Chung L; Chan-Li Y; Collins S; Powell JD; Elisseeff JH; Horton MR; Hillel AT
JCI Insight; 2023 Jun; 8(11):. PubMed ID: 37159282
[TBL] [Abstract][Full Text] [Related]
2. Engineering an immunomodulatory drug-eluting stent to treat laryngotracheal stenosis.
Duvvuri M; Motz K; Murphy M; Feeley M; Ding D; Lee A; Elisseeff JH; Hillel AT
Biomater Sci; 2019 Apr; 7(5):1863-1874. PubMed ID: 30874257
[TBL] [Abstract][Full Text] [Related]
3. Interferon-γ Treatment of Human Laryngotracheal Stenosis-Derived Fibroblasts.
Motz K; Samad I; Yin LX; Murphy MK; Duvvuri M; Ding D; Hillel AT
JAMA Otolaryngol Head Neck Surg; 2017 Nov; 143(11):1134-1140. PubMed ID: 28715559
[TBL] [Abstract][Full Text] [Related]
4. Targeting metabolic abnormalities to reverse fibrosis in iatrogenic laryngotracheal stenosis.
Murphy MK; Motz KM; Ding D; Yin L; Duvvuri M; Feeley M; Hillel AT
Laryngoscope; 2018 Feb; 128(2):E59-E67. PubMed ID: 28940431
[TBL] [Abstract][Full Text] [Related]
5. Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis.
Duvvuri M; Motz K; Tsai HW; Lina I; Ding D; Lee A; Hillel AT
J Vis Exp; 2020 Jan; (155):. PubMed ID: 32065163
[TBL] [Abstract][Full Text] [Related]
6. Metabolic variations in normal and fibrotic human laryngotracheal-derived fibroblasts: A Warburg-like effect.
Ma G; Samad I; Motz K; Yin LX; Duvvuri MV; Ding D; Namba DR; Elisseeff JH; Horton MR; Hillel AT
Laryngoscope; 2017 Mar; 127(3):E107-E113. PubMed ID: 27585358
[TBL] [Abstract][Full Text] [Related]
7. Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis.
Davis RJ; Lina I; Ding D; Engle EL; Taube J; Gelbard A; Hillel AT
Laryngoscope; 2021 May; 131(5):967-974. PubMed ID: 32557663
[TBL] [Abstract][Full Text] [Related]
8. M2 Macrophages Promote Collagen Expression and Synthesis in Laryngotracheal Stenosis Fibroblasts.
Motz K; Lina I; Murphy MK; Drake V; Davis R; Tsai HW; Feeley M; Yin LX; Ding D; Hillel A
Laryngoscope; 2021 Feb; 131(2):E346-E353. PubMed ID: 33051870
[TBL] [Abstract][Full Text] [Related]
9. The heterogeneity of fibroblasts in laryngotracheal stenosis and skin hypertrophic scar in pediatric patients.
Hu B; Wang J; Chen J; Zhao L; Li X
Int J Pediatr Otorhinolaryngol; 2021 Jun; 145():110709. PubMed ID: 33910042
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin inhibits human laryngotracheal stenosis-derived fibroblast proliferation, metabolism, and function in vitro.
Namba DR; Ma G; Samad I; Ding D; Pandian V; Powell JD; Horton MR; Hillel AT
Otolaryngol Head Neck Surg; 2015 May; 152(5):881-8. PubMed ID: 25754184
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable Stent with mTOR Inhibitor-Eluting Reduces Progression of Ureteral Stricture.
Ho DR; Su SH; Chang PJ; Lin WY; Huang YC; Lin JH; Huang KT; Chan WN; Chen CS
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073521
[TBL] [Abstract][Full Text] [Related]
12. Anti-fibrosis activity of quercetin attenuates rabbit tracheal stenosis via the TGF-β/AKT/mTOR signaling pathway.
Xiao Y; Zhou L; Zhang T; Qin C; Wei P; Luo L; Luo L; Huang G; Chen A; Liu G
Life Sci; 2020 Jun; 250():117552. PubMed ID: 32179074
[TBL] [Abstract][Full Text] [Related]
13. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation.
Hasan M; Neumann B; Haupeltshofer S; Stahlke S; Fantini MC; Angstwurm K; Bogdahn U; Kleiter I
Immunol Cell Biol; 2015 Aug; 93(7):662-72. PubMed ID: 25823994
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated Macrophages Are Present in Bleomycin-Induced Murine Laryngotracheal Stenosis.
Hillel AT; Samad I; Ma G; Ding D; Sadtler K; Powell JD; Lane AP; Horton MR
Otolaryngol Head Neck Surg; 2015 Aug; 153(2):244-50. PubMed ID: 26084828
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Inflammatory Markers in Laryngotracheal Stenosis.
Motz KM; Yin LX; Samad I; Ding D; Murphy MK; Duvvuri M; Hillel AT
Otolaryngol Head Neck Surg; 2017 Sep; 157(3):466-472. PubMed ID: 28485188
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms and Physiological Changes behind Benign Tracheal and Subglottic Stenosis in Adults.
Marchioni A; Tonelli R; Andreani A; Cappiello GF; Fermi M; Trentacosti F; Castaniere I; Fantini R; Tabbì L; Andrisani D; Gozzi F; Bruzzi G; Manicardi L; Moretti A; Baroncini S; Samarelli AV; Pinelli M; De Santis G; Stefani A; Marchioni D; Mattioli F; Clini E
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269565
[TBL] [Abstract][Full Text] [Related]
17. Euonymine inhibits in-stent restenosis through enhancing contractile phenotype of vascular smooth muscle cells via modulating the PTEN/AKT/mTOR signaling pathway.
Zhang L; Tao Y; Yang R; Hu Q; Jia J; Yu M; He B; Shen Z; Qin H; Yu Z; Chen P
Phytomedicine; 2022 Dec; 107():154450. PubMed ID: 36174454
[TBL] [Abstract][Full Text] [Related]
18. T-Helper 2 Lymphocyte Immunophenotype Is Associated With Iatrogenic Laryngotracheal Stenosis.
Hillel AT; Ding D; Samad I; Murphy MK; Motz K
Laryngoscope; 2019 Jan; 129(1):177-186. PubMed ID: 30421427
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Inhaled Drug Delivery in Patients With One- and Two-level Laryngotracheal Stenosis.
Gosman RE; Sicard RM; Cohen SM; Frank-Ito DO
Laryngoscope; 2023 Feb; 133(2):366-374. PubMed ID: 35608335
[TBL] [Abstract][Full Text] [Related]
20. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.
Finn AV; John M; Nakazawa G; Polavarapu R; Karmali V; Xu X; Cheng Q; Davis T; Raghunathan C; Acampado E; Ezell T; Lajoie S; Eppihimer M; Kolodgie FD; Virmani R; Gold HK
Circ Res; 2009 Nov; 105(10):1003-12. PubMed ID: 19797172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
